Illumina secured a new $1 billion credit facility with Bank of America and simultaneously launched an underwriting agreement to sell $300 million in notes due 2029. The credit agreement replaces a prior arrangement and includes sublimits for swingline borrowings and letters of credit, with maturity slated for 2031. Illumina said the proceeds from the notes offering will be used together with cash on hand to repay existing notes due in September 2026. The transaction underscores continued capital market utilization by large genomics platforms to manage refinancing schedules and preserve liquidity. For the biotech ecosystem, Illumina’s financing also signals continued investment capacity for sequencing and service-related operations as companies plan for scaling genomics-enabled clinical and research workflows.